FDA accepts Lumizyme BLA

FDA accepted a BLA from Genzyme Corp. (NASDAQ:GENZ) for Lumizyme alglucosidase alfa produced at the 4,000L bioreactor scale to treat Pompe's disease. The agency designated the BLA as a Class 2 complet...